Chronic Myeloid Leukemia

Grade 3 or 4 neutropenia had been observed in 13% patients with chronic myelogenous leukemia (CML), treated on a phase III randomized trial with imatinib. Imatinib does not affect the Philadelphia chromosome negative normal hematopoietic progenitors, and while G-CSF and GM-CSF have been tested without adverse consequences in a phase II trial of this agent, the standard recommendation is to withhold and subsequently restart the therapy, rather than prescribing growth factors.26

0 0

Post a comment